Detection of single nucleotide polymorphisms in the ABCG2 gene in a Dutch population

Tessa M Bosch1, Linda M Kjellberg, Anja Bouwers

  • 1Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute/Slotervaart Hospital, 1066 EC Amsterdam, The Netherlands. aptbo@slz.nl

American Journal of Pharmacogenomics : Genomics-Related Research in Drug Development and Clinical Practice
|April 9, 2005
PubMed
Abstract

Insights

Researchers identified 19 single nucleotide polymorphisms (SNPs) in the ABCG2 gene within a Dutch population, including 7 novel variants. These ABCG2 gene variations may influence drug metabolism and efficacy, particularly for anticancer drugs.

Area of Science:

  • Pharmacogenomics
  • Molecular Biology
  • Genetics

Background:

  • The ATP-binding cassette transporter ABCG2 (also known as Breast Cancer Resistance Protein) plays a crucial role in cellular defense against xenobiotics.
  • Overexpression of ABCG2 in cancer cells contributes to multidrug resistance (MDR) against various chemotherapy agents.
  • Significant inter-individual variability exists in the pharmacokinetics of drugs transported by ABCG2, potentially linked to genetic variations.

Purpose of the Study:

  • To systematically screen the ABCG2 gene for single nucleotide polymorphisms (SNPs) in a healthy Dutch population.
  • To determine the allele frequencies of known and novel SNPs within the ABCG2 gene.

Main Methods:

  • Genomic DNA was isolated from blood samples of 100 healthy Dutch volunteers (79% female, 21% male).
  • Polymerase chain reaction (PCR) amplification followed by DNA sequencing was employed to identify SNPs.
  • The study population was predominantly of Caucasian ethnicity (93%).

Main Results:

  • A total of 19 SNPs were identified in the ABCG2 gene.
  • Seven of the identified SNPs were previously unreported.
  • Notable SNPs include G8883A (R160Q) in exon 5 and C44168T (R575X) in exon 14, both resulting in amino acid substitutions. Many novel SNPs were located in intronic regions.

Conclusions:

  • The identified SNPs in the ABCG2 gene provide a basis for future investigations into their functional impact.
  • Further research will explore how these genetic variations affect ABCG2 protein expression, activity, and substrate interactions.
  • These findings can contribute to understanding the influence of ABCG2 genetic polymorphisms on the pharmacokinetics of anticancer drugs.

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Comparing Copy Number Variations and SNPs02:26

Comparing Copy Number Variations and SNPs

Sequencing of the human genome has opened up several best-kept secrets of the genome. Scientists have identified thousands of genome variations that exist within a population. These variations can be a single nucleotide or a larger chromosomal variation.
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...